NYSE:SNY
Sanofi Stock News
$50.36
+1.41 (+2.88%)
At Close: May 22, 2024
Wide-Moat Stocks On Sale - The May 2021 Heat Map
01:31pm, Friday, 23'rd Apr 2021
Our 3-step process focuses on wide-moat stocks (as per Morningstar's rating). e are only interested in those targets that are attractively valued in historical comparison.
Analysts See Plenty of Upside for Replimune
03:19pm, Thursday, 22'nd Apr 2021
Boston-area biotech Replimune Group Inc. (NASDAQ:REPL) just boosted its executive lineup with a heavy hitter, and the market seems to like the addition.
Kazia Licenses Global Rights to EVT801, a Novel, First-in-Class, Clinic-Ready, VEGFR3 Inhibitor, from Evotec SE
05:36am, Monday, 19'th Apr 2021
SYDNEY, April 19, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an oncology-focused drug development company, is pleased to announce that it has entered into a worldwide ex
3 Biotech Stocks Ripe for Spring Portfolio Cleaning
06:30am, Friday, 16'th Apr 2021
All down 45% or more from their 52-week highs, should you consider cutting your losses?
BOE: Global Exposure At A Discount
08:29am, Tuesday, 13'th Apr 2021
BOE: Global Exposure At A Discount
Sanofi (SNY) Acquires Tidal to Aid mRNA-Based Research Platform
09:51am, Monday, 12'th Apr 2021
Sanofi's (SNY) acquisition of Tidal Therapeutics for $160 million is set to aid innovative mRNA-based research platform with applications in oncology, immunology and other diseases.
Sanofi forms nonprofit unit to provide essential medicines to some low-income countries
07:48am, Wednesday, 07'th Apr 2021
U.S.-listed shares of Sanofi gained 0.7% in premarket trading on Wednesday after the company said it has formed a nonprofit business unit that will provide 30 essential medicines to 40 lower-income co
Sanofi expands its social commitments, creates nonprofit unit to provide poorest countries with access to essential medicines
07:00am, Wednesday, 07'th Apr 2021
PARIS, April 7, 2021 /PRNewswire/ -- In an open letter, Sanofi Chief Executive Officer Paul Hudson today outlined several key projects that the company will implement to increase the impact of its Co
Is the Market For a Flu Vaccine Disappearing?
06:20am, Sunday, 04'th Apr 2021
There are five billion reasons these companies hope it's not.
A Trio of High Earnings Return Stocks
10:58am, Friday, 02'nd Apr 2021
They are yielding twice the monthly spot rate on 20-year high-quality market corporate bonds
This 2020 Biotech IPO Is Poised to Break Out in 2021
06:15am, Friday, 02'nd Apr 2021
Revolution Medicines' leading compound is shaping up to be a platform in a pill.
Sanofi (SNY) Gets FDA Approval for Sarclisa Label Expansion
09:51am, Thursday, 01'st Apr 2021
Sanofi's (SNY) Sarclisa gets FDA approval to treat multiple myeloma patients who have received one to three prior lines of therapy in combination with Kyprolis and dexamethasone.
PARIS, March 31, 2021 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved Sarclisa® (isatuximab-irfc) in combination with carfilzomib and dexamethasone (Kd), for the treatment
Daiichi Axes Sanofi Vaccine Pact After Pertussis Jab Manufacturing Faces Snag
01:46pm, Wednesday, 31'st Mar 2021
Though Daiichi Sankyo (OTCMKTS: DSNKY) and Sanofi SA (NASDAQ: SNY) came forward to help produce other pharmas' COVID-19 shots, the companies are calling it quits on their own, separate vaccine al
Canadian Government, Sanofi To Build C$925M Flu Vaccine Facility In Toronto
11:57am, Wednesday, 31'st Mar 2021
Sanofi SA (NASDAQ: SNY) is dropping a major investment into its supply chain by shelling C$925 million to build a new manufacturing facility in Toronto. The new facility will be operational by 202